Aerie pharmaceuticals completes enrollment of its phase 2b clinical trial of ar-15512 (trpm8 agonist) ophthalmic solution for the treatment of patients with dry eye disease

Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq: aeri), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the completion of patient enrollment for comet-1, a phase 2b clinical trial of ar-15512 (trpm8 agonist) (“ar-15512”) ophthalmic solution for the treatment of patients with dry eye d
AERI Ratings Summary
AERI Quant Ranking